Advanced Bioadjuvant LLC’s Adjuplex adjuvants for use with vaccines against infectious diseases

THIS IS A NOTICE OF INTENT AND NOT A REQUEST FOR QUOTATIONS. 

This notice is published in accordance with Federal Acquisition Regulation (FAR) 5.101(a)(1) requiring the dissemination of information regarding proposed contract actions. This is a Notice of Intent to award a sole source, firm-fixed price task order pursuant to FAR 8.405-6(a)(1)(B) – Only one source can provide the services required.  

The National Institute of Allergy and Infectious Diseases (NIAID) intends to negotiate on a sole source basis with Advanced Bioadjuvants, LLC. (“ABA”). DUNS: 180049798, Address:

5321 SOUTH 162ND AVE OMAHA, NE, 68135-3118

This requirement is for ability to use Advanced Bioadjuvant LLC’s adjuvant technology known as Adjuplex. More specifically, it is for a non-exclusive, fee-bearing, worldwide license to ABA’s patents, trademark, and know how to make, use, and distribute, including export, Adjuplex for manufacture of current Good Manufacturing Process (cGMP) grade material, research material, and both clinical and research evaluation of this material with vaccines/immunogens designed to prevent human infectious diseases. 

Period of Performance:

The estimated period of performance required for total performance if all option periods are exercised is from September 26, 2021 – September 25, 2026.

Other Information:

The North American Industry Classification (NAICS) code for this acquisition is 541714 – Research and Development in Biotechnology (except Nanobiotechnology), which has a size standard of 1,000. ABA is a small business under this NAICS code.

This will be the only notice of the Government's intent to solicit, negotiate, and award to one source to satisfy this requirement. The Government plans to award a contract for this requirement within fourteen (14) days of this notice.

While this synopsis does not constitute a solicitation, interested vendors may identify their interest and capability to satisfy this requirement. The Government understands that ABA is the only vendor which can provide the Adjuplex license and technology. However, firms that believe they can provide the capability required to fully meet the Government's requirement may submit a capabilities statement, including past performance, in writing to the identified point of contact within seven (7) calendar days after the publication of this notice. Such documentation shall be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. Interested parties may identify their interest and capability to respond to the requirement or submit offers on NIAID_NOI21_2063418.

This notice does not obligate the Government to award a contract or otherwise pay for any information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted.

For additional information or to submit responses, please contact Lu Chang, Contract Specialist at lu-chang.lu@nih.gov